← Back to all trials
Completed
NCT06153498
PK/PD Properties and Safety of Remazolam Besylate for Injection in ICU Patients With Impaired Renal Function
Conditions: Mechanically Ventilated Patients
Sex: All
Ages: 18 Years – 80 Years
Healthy volunteers: No
Phase: NA
Enrollment: 36
Sponsor: Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Location: Wuhan Union Hospital Wuhan Hubei
Summary
Pharmacokinetic/pharmacodynamic profiles of remazolam besylate were compared in patients with impaired and normal renal function in the ICU, and safety was assessed by recording hemodynamic parameters and adverse events.
Eligibility Criteria
Inclusion Criteria:
* Age ≥18 and ≤80 years, regardless of gender;
* Anticipated requirement for mechanical ventilation and sedation ≥24 hours;
* arget sedation level within RASS score range of -3 to 0 (inclusive);
Patients with renal impairment were defined as having a glomerular filtration rate (GFR) \
Source: ClinicalTrials.gov (NCT06153498). StuddyBuddy aggregates publicly available trial information.
